Combination Probiotic for Autism
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a combination probiotic treatment, BB-12 with LGG, to determine its safety and tolerability in children with autism spectrum disorders (ASD) who also have gastrointestinal issues. Researchers aim to understand how different doses of the probiotic affect behaviors, gut symptoms, and biological markers related to inflammation and gut health. The trial compares two doses of the probiotic to a placebo, a look-alike substance with no active ingredient. Children with ASD who have ongoing gut problems and have not used probiotics in the last month may be suitable for this study. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group.
Will I have to stop taking my current medications?
The trial requires that participants do not take any other probiotic-containing products, including yogurt with probiotics, during the study. If you are taking immunosuppressive medications, oral corticosteroids, or have used probiotics, oral antibiotics, or antifungals recently, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that the combination of probiotics BB-12 and LGG is generally safe. Studies have found no major side effects when used together. BB-12 and LGG rank among the most researched probiotics worldwide. In the USA, they are considered safe to eat, meaning most people can take them without issues.
Even at varying amounts, no strong evidence suggests they cause harm. These probiotics often support gut health and have been tested in many situations. Overall, the safety data appears promising for those considering joining a trial with these probiotics.12345Why are researchers excited about this trial?
Most treatments for autism focus on behavioral therapy or medications that target symptoms like irritability and hyperactivity. But this new combination probiotic treatment is different because it uses specific strains of beneficial bacteria, BB-12 and LGG, to potentially improve gut health and, in turn, influence brain function. Researchers are excited because this approach taps into the gut-brain connection, which is a relatively new area of exploration in autism. The treatment comes in two doses—one with 1 billion CFUs and a higher dose with 10 billion CFUs—offering a non-invasive option that could complement existing therapies without the side effects often associated with medication.
What evidence suggests that this trial's treatments could be effective for autism?
This trial will compare different doses of the probiotics BB-12 and LGG to a placebo in children with autism. Research has shown that these probiotics might help with autism-related symptoms. Studies have found improvements in gut health, often linked to behavior in children with autism. Additionally, they may protect certain brain cells, suggesting potential benefits for brain-related conditions. Although research remains in the early stages, these findings indicate that the probiotics might benefit children with autism. More research is needed to confirm these effects, but initial results are promising.12678
Who Is on the Research Team?
J Marc RHoads, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Are You a Good Fit for This Trial?
This trial is for healthy children aged 4-16 with autism spectrum disorders and gastrointestinal symptoms, without other illnesses. It's open to all races and genders; girls who can have babies will get a pregnancy test each visit. Kids can't join if they're on laxatives, have certain GI diseases, allergies to antibiotics, fever or serious health issues, are pregnant/breastfeeding, take immune-weakening drugs or had recent antibiotics/probiotics.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BB-12 with LGG at different doses over a 56-day period
Observation
Participants are observed for effects on behaviors, GI symptoms, and biomarkers
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BB-12 with LGG (Higher Dose)
- BB-12 with LGG (Lower Dose)
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center, Houston
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Texas Higher Education Coordinating Board
Collaborator
Texas Higher Education Coordinating Board
Collaborator